The Company’s products are targeted to treat adult patients.
Protocols are being developed for patients with the following indications:

• Hematological Malignancy:
  1. Chronic Lymphocytic Leukemia
  2. Non-Hodgkins Lymphoma
  3. Multiple Myeloma
• Prostate Cancer (primary and metastatic)
• Breast Cancer (primary and metastatic)
• Glioblastoma Multiforme brain tumor
• Colorectal Cancer with liver metastases
• Kidney Cancer
• Non-Small Cell Lung Cancer